Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Tuesday, up 2.43% from the previous trading day ,before settling in for the closing price of $53.81. Over the past 52 weeks, APLS has traded in a range of $19.83-$94.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 73.14%. While this was happening, its average annual earnings per share was recorded 79.73%. With a float of $98.84 million, this company’s outstanding shares have now reached $119.56 million.
Considering the fact that the conglomerate employs 706 people, you should pay attention to its efficiency factor.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 18.03%, while institutional ownership is 91.85%. The most recent insider transaction that took place on Apr 08 ’24, was worth 3,743,605. In this transaction Chief Scientific Officer of this company sold 69,107 shares at a rate of $54.17, taking the stock ownership to the 1,115,983 shares. Before that another transaction happened on Apr 01 ’24, when Company’s Chief Financial Officer sold 4,000 for $58.66, making the entire transaction worth $234,640. This insider now owns 93,338 shares in total.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.73 earnings per share (EPS), lower than consensus estimate (set at -$0.69) by -$0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.30% during the next five years compared to -13.70% drop over the previous five years of trading.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 2.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.48, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach 1.43 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Compared to the last year’s volume of 1.5 million, its volume of 0.84 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 17.93%. Additionally, its Average True Range was 2.57.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 32.10%, which indicates a significant increase from 28.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.45% in the past 14 days, which was lower than the 65.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.10, while its 200-day Moving Average is $53.87. Nevertheless, the first resistance level for the watch stands at $55.82 in the near term. At $56.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $57.70. If the price goes on to break the first support level at $53.94, it is likely to go to the next support level at $52.75. Now, if the price goes above the second support level, the third support stands at $52.06.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
The company with the Market Capitalisation of 6.65 billion has total of 120,582K Shares Outstanding. Its annual sales at the moment are 396,590 K in contrast with the sum of -528,630 K annual income. Company’s last quarter sales were recorded 146,380 K and last quarter income was -88,580 K.
